Recent Updates
Recently added Catalysts
SRRK Positive Sentiment

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Tuesday, October 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Scholar Rock has announced its plans to report third quarter 2026 financial results on November 10, 2026. The report will be released before the market opens, followed by a conference call with management at 8:00 a.m. ET. Investors can access the webcast through the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scholar Rock is actively engaging with investors.
  • The company is transparent about its financial reporting schedule.
  • The conference call provides an opportunity for direct communication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
7.9%
average across 12 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
SRK-181
Phase 1 · Cancer

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, pleas

Frequently Asked Questions

When will Scholar Rock report its Q3 2026 results?

Scholar Rock will report its Q3 2026 financial results on November 10, 2026.

What time is the Scholar Rock conference call?

The conference call is scheduled for 8:00 a.m. ET on November 10, 2026.

How can I access the Scholar Rock webcast?

The webcast can be accessed through the 'Events and Presentations' section on the Scholar Rock website.

ShareAdd on Google
Tags: SRRK Scholar Rock financial results Q3 2026 conference call
Last updated: Oct 20, 2026

Biotech snapshot

Cash runway
$492M liquidity · $23M/mo burn
~19 mo
Low dilution risk
Lead asset
SRK-181Phase 1
Cancer →

Catalyst track record

+10%
best trade around SRRK's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for SRRK.

See every catalyst's timing & PoA →